114 related articles for article (PubMed ID: 9517495)
1. The diagnostic and prognostic value of bone marrow immunostaining in myelodysplastic syndromes.
Lambertenghi Deliliers G; Annaloro C; Soligo D; Oriani A
Leuk Lymphoma; 1998 Jan; 28(3-4):231-9. PubMed ID: 9517495
[TBL] [Abstract][Full Text] [Related]
2. Primary myelodysplastic syndromes: diagnostic and prognostic significance of immunohistochemical assessment of bone marrow biopsies.
Mangi MH; Mufti GJ
Blood; 1992 Jan; 79(1):198-205. PubMed ID: 1370203
[TBL] [Abstract][Full Text] [Related]
3. Abnormal localization of immature precursors (ALIP) in the bone marrow of myelodysplastic syndromes: current state of knowledge and future directions.
Mangi MH; Salisbury JR; Mufti GJ
Leuk Res; 1991; 15(7):627-39. PubMed ID: 1861544
[TBL] [Abstract][Full Text] [Related]
4. Bone marrow histology and CD34 immunostaining in the prognostic evaluation of primary myelodysplastic syndromes.
Oriani A; Annaloro C; Soligo D; Pozzoli E; Cortelezzi A; Lambertenghi Deliliers G
Br J Haematol; 1996 Feb; 92(2):360-4. PubMed ID: 8603000
[TBL] [Abstract][Full Text] [Related]
5. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
Orazi A
Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
[TBL] [Abstract][Full Text] [Related]
6. CD34 immunohistochemistry of bone marrow biopsies: prognostic significance in primary myelodysplastic syndromes.
Soligo DA; Oriani A; Annaloro C; Cortelezzi A; Calori R; Pozzoli E; Nosella D; Orazi A; Deliliers GL
Am J Hematol; 1994 May; 46(1):9-17. PubMed ID: 7514357
[TBL] [Abstract][Full Text] [Related]
7. Prognostic evaluation of ALIP and CD34 immunostaining in IPSS-R subgroups of myelodysplastic syndromes.
Xiong B; Nie Y; Tang Z; Xue M; Zuo X
Pathology; 2017 Aug; 49(5):526-533. PubMed ID: 28669578
[TBL] [Abstract][Full Text] [Related]
8. Clinical, hematological and histomorphological profile of myelodysplastic syndrome.
Nigam S; Rani S; Singh T; Gupta S; Rakheja D; Gaiha M
J Assoc Physicians India; 2001 Apr; 49():430-4. PubMed ID: 11762613
[TBL] [Abstract][Full Text] [Related]
9. CD34 immunohistochemical staining of bone marrow biopsies in myelodysplastic syndromes.
Min YH; Lee ST; Min DW; Kim TS; Lee CH; Lee BK; Hahn JS; Ko YW
Yonsei Med J; 1995 Mar; 36(1):1-8. PubMed ID: 7537931
[TBL] [Abstract][Full Text] [Related]
10. Additional prognostic value of bone marrow histology in patients subclassified according to the International Prognostic Scoring System for myelodysplastic syndromes.
Verburgh E; Achten R; Maes B; Hagemeijer A; Boogaerts M; De Wolf-Peeters C; Verhoef G
J Clin Oncol; 2003 Jan; 21(2):273-82. PubMed ID: 12525519
[TBL] [Abstract][Full Text] [Related]
11. [Diagnosis and therapy strategy in myelodysplastic syndromes].
Gattermann N; Aul C
Praxis (Bern 1994); 1996 Jan; 85(3):39-44. PubMed ID: 8578048
[TBL] [Abstract][Full Text] [Related]
12. Surface marker abnormalities in myelodysplastic syndromes.
Elghetany MT
Haematologica; 1998 Dec; 83(12):1104-15. PubMed ID: 9949628
[TBL] [Abstract][Full Text] [Related]
13. Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: a pilot study on a series of 56 patients.
Matarraz S; López A; Barrena S; Fernandez C; Jensen E; Flores-Montero J; Rasillo A; Sayagues JM; Sánchez ML; Bárcena P; Hernandez-Rivas JM; Salvador C; Fernandez-Mosteirín N; Giralt M; Perdiguer L; Laranjeira P; Paiva A; Orfao A
Cytometry B Clin Cytom; 2010 May; 78(3):154-68. PubMed ID: 20198685
[TBL] [Abstract][Full Text] [Related]
14. [Abnormalities of CD34+ cells differentiation and bone marrow cell cycle in myelodysplastic syndrome].
Li LJ; Fu R; Shao ZH; Wang HQ; Yue LZ; Ruan EB; Liu H; Wang J; Wang HL
Zhonghua Nei Ke Za Zhi; 2010 Nov; 49(11):963-6. PubMed ID: 21211213
[TBL] [Abstract][Full Text] [Related]
15. Prognostic relevance of histological findings on bone marrow biopsy in myelodysplastic syndromes.
Lambertenghi-Deliliers G; Annaloro C; Oriani A; Soligo D; Pozzoli E; Polli EE
Ann Hematol; 1993 Feb; 66(2):85-91. PubMed ID: 8448244
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow histology in myelodysplastic syndromes. II. Prognostic value of abnormal localization of immature precursors in MDS.
Tricot G; De Wolf-Peeters C; Vlietinck R; Verwilghen RL
Br J Haematol; 1984 Oct; 58(2):217-25. PubMed ID: 6477833
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical detection of p53, mdm2, waf1/p21, and Ki67 proteins in bone marrow biopsies in myelodysplastic syndroms, acute myelogenous leukaemias and chronic myeloproliferative disorders.
Kanavaros P; Stefanaki K; Rontogianni D; Darivianaki K; Vlychou M; Papadaki E; Eliopoulos G; Bakiri M; Matsouka C; Kakolyris S; Georgoulias V
Clin Exp Pathol; 1999; 47(5):231-8. PubMed ID: 10598372
[TBL] [Abstract][Full Text] [Related]
18. Therapy-related myelodysplastic syndromes: FAB classification, bone marrow histology, and immunohistology in the prognostic assessment.
Orazi A; Cattoretti G; Soligo D; Luksch R; Lambertenghi-Deliliers G
Leukemia; 1993 Jun; 7(6):838-47. PubMed ID: 7684797
[TBL] [Abstract][Full Text] [Related]
19. [Pathohistological characteristics of myelodysplastic syndromes: diagnostic and prognostic significance].
Marisavljević D; Cemerikić V; Rolović Z; Bosković D; Colović M
Srp Arh Celok Lek; 2005; 133(3-4):162-9. PubMed ID: 16206706
[TBL] [Abstract][Full Text] [Related]
20. [The implications of the biological indices examination of bone marrow cells in myelodysplastic syndromes].
Zhang F; Hao Y; Pang W
Zhonghua Xue Ye Xue Za Zhi; 2001 Oct; 22(10):528-32. PubMed ID: 11769678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
